

FOR IMMEDIATE RELEASE:

Morphogenesis, Inc. Announces ImmuneFx™ Pre-clinical Results

April 20, 2005, Tampa, Florida — Morphogenesis, Inc. announced today that its cancer therapy, ImmuneFx™, was able to induce tumor regression in mice with an aggressive form of cancer. The news was made public at the 96th Annual Meeting of the American Association for Cancer Research in Anaheim, California where basic and clinical researchers gathered to review the latest discoveries in diagnosis, treatment and prevention of cancer.

ImmuneFx, a novel form of immunotherapy, which may eventually be used to treat many types of cancer, was tested against neuroblastoma. The pre-clinical model mimics human neuroblastoma, a particularly devastating cancer in children which currently has no cure. Unchecked, mice with this tumor succumb within two weeks. “In the past, the treatments available to children affected by this disease have had limited success and have caused major side-effects,” say company officials.

ImmuneFx is a non-invasive therapy that stimulates the immune system to fight tumors. Morphogenesis researchers and its collaborators believe that ImmuneFx works by priming the body’s immune system to attack the cancer cells much like it fights off infection. It has been known for many years that the body can kill tumor cells under the right conditions, but in advanced disease states, it is unable to prevent tumor growth. Morphogenesis believes that the success of the ImmuneFx™ trials were due to its ability to stimulate a powerful tumor-specific immune response.

Dr. Pat Lawman, CEO of Morphogenesis, stated that “The results of these studies exceeded our expectations. The fact that ImmuneFx was able to stimulate complete tumor regression in eighty-one percent of animals tested and at the highest dose exhibited a survival rate of better than eighty-eight percent speaks to the tremendous potential of this treatment. Even those animals which eventually succumbed, lived four times longer than their untreated counterparts.”

The large number of experimental animals, the long-term follow-up and the conclusive nature of the data generated by these studies make company officials confident that its near-term plans to enter into Phase I/II human clinical trials will be equally successful.

ABOUT MORPHOGENESIS:

Morphogenesis is a privately-held biotechnology company which specializes in cell therapy. The Company is also developing proprietary stem cell products, including its prototype cell separation device, which was completed earlier this month. For more information about Morphogenesis, contact Dr. Lawman at 813 855 9844 or log onto www.morphogenesis-inc.com.

Forward-Looking Statements:

Statements in this press release that are not strictly historical may be “forward-looking” statements, which involve risks and uncertainties. There can be no assurance that Morphogenesis, Inc. will be able to commercially develop cancer vaccine therapy, cell separation device or stem cell products; that the proposed products will prove to be safe and/or effective, that any clinical trials will be successful, or that necessary regulatory approvals will be obtained.

Morphogenesis, Inc. | 209 State Street | Oldsmar, FL 34677
Telephone: (813) 855-9844 | Fax: (813) 854-2340 | email: plawman@morphogenesis-inc.com